FDA Halted Distribution of O.N. Diagnostics Software
The agency cited unauthorized architectural changes in an updated machine-learning vertebral tool.
Updated on Oct. 7, 2026 in Software
Live Poll
Should medical software developers be required to submit all significant product updates for federal regulatory review?
On September 1, 2026, the FDA issued a warning letter to O.N. Diagnostics, ordering the firm to stop the commercial distribution of its VirtuOst version 3.0.0 software. The regulator determined that the software update was distributed without the necessary clearance.
Why it matters
The FDA mandates 510(k) submissions for any modifications that could impact the safety or effectiveness of medical devices. This action underscores the regulatory scrutiny facing software manufacturers that update clinical tools without prior agency review.
The VirtuOst version 3.0.0 software update moved from a traditional desktop architecture to a web-based platform and introduced a machine-learning algorithm for vertebral landmarking. These architectural and functional changes prompted the FDA to request a new 510(k) submission.
The players
O.N. Diagnostics
A medical software developer specializing in diagnostic imaging tools and vertebral fracture assessment technologies.
FDA
The United States federal agency responsible for overseeing the safety, efficacy, and regulatory compliance of medical devices.
The details
VirtuOst is used for vertebral fracture assessment, and the update in question integrated a machine-learning algorithm—a subset of artificial intelligence where software identifies patterns in data—designed to perform vertebral landmarking. By migrating the system from a localized desktop application to a web-based architecture, the company fundamentally altered the device delivery. The FDA determined these technical shifts required a new safety and effectiveness review, which the company bypassed.
Timeline
September 1, 2026: The FDA issued a formal warning letter to O.N. Diagnostics.
The Tech Race
The FDA's action reflects a broader trend in oversight for software-as-a-medical-device platforms. It marks a firm enforcement of the 510(k) premarket notification process, requiring developers to pause deployments when software updates cross the threshold of clinical change.
Clinicians and hospital systems utilizing VirtuOst version 3.0.0 must halt use of the software immediately following the FDA distribution order. Patients and providers should consult with their diagnostic imaging departments to determine if alternative software or manual review protocols are currently required.
The takeaway
Regulatory bodies are applying increased scrutiny to the versioning cycles of diagnostic AI. Organizations in the space should monitor the FDA's enforcement database to track when O.N. Diagnostics successfully completes its required 510(k) submission for the updated software.
Further reading
For more on the intersection of medical software and regulatory compliance, explore our Software coverage.
Source note: This article includes information reported by AuntMinnie.
Live Poll
Should medical software developers be required to submit all significant product updates for federal regulatory review?
